Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EvoTears
- Development stage
- Unknown
- Lead developer
- Novaliq
- Modality
- Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
EvoTears is a water-free, preservative-free ophthalmic lubricant developed by Ursapharm in partnership with Novaliq for the treatment of evaporative dry eye disease. Its active ingredient is perfluorohexyloctane, a semi-fluorinated alkane that acts as a physical lipid layer replacement. Upon application, it forms a thin, protective film over the tear film, stabilizing the lipid phase and preventing the evaporation of the underlying aqueous layer. Unlike traditional eye drops, it contains no water, preservatives, or emulsifiers, and it received CE mark approval as a medical device in 2013.
- Brand names
- EvoTearsHYLO LIPIDHycosan Shield
- Other names
- perfluorohexyloctane
Beyond the preview
Go deeper on EvoTears.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EvoTears.